Michael King
Stock Analyst at Rodman & Renshaw
(0.90)
# 3,878
Out of 5,182 analysts
110
Total ratings
36.21%
Success rate
-10.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $17 | $1.06 | +1,503.77% | 1 | Mar 17, 2026 | |
| KPTI Karyopharm Therapeutics | Initiates: Buy | $28 | $8.00 | +250.00% | 1 | Mar 10, 2026 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $17 | $10.15 | +67.49% | 1 | Mar 10, 2026 | |
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $13.60 | +4,679.41% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $1.97 | +458.38% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.87 | +1,611.23% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $0.80 | +8,437.95% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $11.95 | +1,573.64% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.85 | +877.62% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $748.87 | +15.11% | 11 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $44.27 | -45.79% | 10 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $166 | $3.96 | +4,091.92% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $12.42 | +238.16% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $322.11 | -5.62% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $13.49 | +759.90% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.17 | +99.23% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $49.96 | -51.96% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $70.10 | -34.38% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $32.92 | +191.62% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $504 | $8.51 | +5,822.44% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $36.37 | -14.76% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $799.65 | -95.50% | 2 | Nov 13, 2017 |
BioXcel Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: $17
Current: $1.06
Upside: +1,503.77%
Karyopharm Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $28
Current: $8.00
Upside: +250.00%
Elicio Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $17
Current: $10.15
Upside: +67.49%
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $13.60
Upside: +4,679.41%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $1.97
Upside: +458.38%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.87
Upside: +1,611.23%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $0.80
Upside: +8,437.95%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $11.95
Upside: +1,573.64%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.85
Upside: +877.62%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $748.87
Upside: +15.11%
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.27
Upside: -45.79%
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.96
Upside: +4,091.92%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $12.42
Upside: +238.16%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $322.11
Upside: -5.62%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $13.49
Upside: +759.90%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.17
Upside: +99.23%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $49.96
Upside: -51.96%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $70.10
Upside: -34.38%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $32.92
Upside: +191.62%
Jan 10, 2022
Initiates: Buy
Price Target: $504
Current: $8.51
Upside: +5,822.44%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $36.37
Upside: -14.76%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $799.65
Upside: -95.50%